Clinical trial
A Prospective Non-Interventional Study to Describe the Effectiveness of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Patients With Indolent Systemic Mastocytosis and Symptoms That Are Not Adequately Controlled With Symptomatic Treatments in Real-World Settings
NCT07255638 is registered in ClinicalTrials.gov with Blueprint Medicines Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective Non-Interventional Study to Describe the Effectiveness of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Patients With Indolent Systemic Mastocytosis and Symptoms That Are Not Adequately Controlled With Symptomatic Treatments in Real-World Settings
- Lead sponsor
- Blueprint Medicines Corporation
- Phase
- Observational
- Overall status
- Recruiting
- Start date
- December 9, 2025
- Completion date
- December 1, 2028
- Enrollment
- 80 (estimated)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.
indolent systemic mastocytosis